Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 20 | 2020 | 2576 | 2.950 |
Why?
|
| Magnetic Resonance Imaging | 18 | 2023 | 7702 | 1.730 |
Why?
|
| Computed Tomography Angiography | 4 | 2019 | 234 | 1.700 |
Why?
|
| Soft Tissue Neoplasms | 4 | 2020 | 882 | 1.570 |
Why?
|
| Fluorodeoxyglucose F18 | 8 | 2015 | 1226 | 1.290 |
Why?
|
| Image Enhancement | 5 | 2019 | 561 | 1.240 |
Why?
|
| Gadolinium | 3 | 2020 | 164 | 1.180 |
Why?
|
| Contrast Media | 6 | 2023 | 1472 | 1.110 |
Why?
|
| Whole Body Imaging | 4 | 2020 | 114 | 1.060 |
Why?
|
| Tomography, X-Ray Computed | 19 | 2020 | 7551 | 1.040 |
Why?
|
| Radiopharmaceuticals | 8 | 2020 | 1301 | 1.010 |
Why?
|
| Free Tissue Flaps | 2 | 2019 | 372 | 0.950 |
Why?
|
| Positron-Emission Tomography | 11 | 2015 | 2173 | 0.940 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2020 | 833 | 0.890 |
Why?
|
| Musculoskeletal Diseases | 3 | 2023 | 81 | 0.870 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 3 | 2020 | 341 | 0.870 |
Why?
|
| Osteosarcoma | 3 | 2017 | 929 | 0.770 |
Why?
|
| Image Interpretation, Computer-Assisted | 4 | 2013 | 592 | 0.740 |
Why?
|
| Nephrogenic Fibrosing Dermopathy | 1 | 2019 | 10 | 0.730 |
Why?
|
| Scapula | 1 | 2019 | 37 | 0.690 |
Why?
|
| Bone Transplantation | 1 | 2019 | 134 | 0.650 |
Why?
|
| Fibula | 1 | 2018 | 146 | 0.580 |
Why?
|
| Thigh | 2 | 2016 | 172 | 0.550 |
Why?
|
| Fracture Fixation, Internal | 2 | 2008 | 76 | 0.520 |
Why?
|
| Multimodal Imaging | 3 | 2014 | 550 | 0.520 |
Why?
|
| Radiography | 10 | 2023 | 1904 | 0.510 |
Why?
|
| Sarcoma, Ewing | 2 | 2017 | 406 | 0.510 |
Why?
|
| Pattern Recognition, Automated | 1 | 2014 | 125 | 0.470 |
Why?
|
| Radiography, Thoracic | 2 | 2012 | 462 | 0.450 |
Why?
|
| Tomography, Emission-Computed | 2 | 2012 | 310 | 0.420 |
Why?
|
| Preoperative Care | 2 | 2019 | 1529 | 0.400 |
Why?
|
| Bony Callus | 2 | 2008 | 5 | 0.400 |
Why?
|
| Fracture Healing | 2 | 2008 | 40 | 0.390 |
Why?
|
| Spinal Diseases | 1 | 2011 | 125 | 0.380 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 2 | 2020 | 160 | 0.370 |
Why?
|
| Surgical Flaps | 1 | 2016 | 927 | 0.360 |
Why?
|
| Pacemaker, Artificial | 1 | 2012 | 213 | 0.360 |
Why?
|
| Defibrillators, Implantable | 1 | 2012 | 221 | 0.360 |
Why?
|
| Sarcoma | 1 | 2020 | 1725 | 0.350 |
Why?
|
| Hyperostosis | 1 | 2009 | 8 | 0.350 |
Why?
|
| Osteitis | 1 | 2009 | 17 | 0.350 |
Why?
|
| Ilizarov Technique | 1 | 2008 | 4 | 0.340 |
Why?
|
| Humans | 49 | 2024 | 261506 | 0.330 |
Why?
|
| Breast Neoplasms | 9 | 2016 | 15694 | 0.330 |
Why?
|
| Bone Diseases | 1 | 2009 | 143 | 0.310 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2020 | 10035 | 0.310 |
Why?
|
| Fractures, Ununited | 2 | 2008 | 13 | 0.300 |
Why?
|
| Osteopetrosis | 1 | 2006 | 26 | 0.290 |
Why?
|
| Sensitivity and Specificity | 6 | 2013 | 4971 | 0.280 |
Why?
|
| Median Neuropathy | 1 | 2006 | 4 | 0.280 |
Why?
|
| Lipomatosis | 1 | 2006 | 24 | 0.270 |
Why?
|
| Fractures, Bone | 1 | 2008 | 291 | 0.270 |
Why?
|
| Fingers | 1 | 2006 | 120 | 0.260 |
Why?
|
| Muscle Weakness | 1 | 2006 | 116 | 0.250 |
Why?
|
| Hamartoma | 1 | 2006 | 115 | 0.250 |
Why?
|
| Tibial Fractures | 2 | 2002 | 58 | 0.250 |
Why?
|
| Algorithms | 3 | 2013 | 3890 | 0.250 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2024 | 1648 | 0.240 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2003 | 52 | 0.230 |
Why?
|
| Neoplasm Metastasis | 3 | 2011 | 5112 | 0.220 |
Why?
|
| Radionuclide Imaging | 3 | 2011 | 660 | 0.210 |
Why?
|
| Subclavian Artery | 1 | 2001 | 80 | 0.200 |
Why?
|
| Thoracic Outlet Syndrome | 1 | 2001 | 25 | 0.200 |
Why?
|
| Radius | 1 | 2000 | 42 | 0.190 |
Why?
|
| Adult | 20 | 2016 | 77950 | 0.190 |
Why?
|
| Bone and Bones | 2 | 2017 | 619 | 0.180 |
Why?
|
| Lumbosacral Region | 1 | 2019 | 49 | 0.180 |
Why?
|
| Female | 25 | 2020 | 141928 | 0.180 |
Why?
|
| Middle Aged | 18 | 2020 | 86204 | 0.170 |
Why?
|
| Risk Assessment | 4 | 2019 | 6869 | 0.170 |
Why?
|
| Diagnostic Imaging | 2 | 2020 | 1162 | 0.160 |
Why?
|
| Wilms Tumor | 1 | 2001 | 292 | 0.160 |
Why?
|
| Aged | 14 | 2020 | 70117 | 0.160 |
Why?
|
| Perforator Flap | 1 | 2019 | 93 | 0.160 |
Why?
|
| Radiology | 1 | 2023 | 434 | 0.150 |
Why?
|
| Reproducibility of Results | 4 | 2013 | 6009 | 0.150 |
Why?
|
| Neoplasm Staging | 9 | 2015 | 13658 | 0.150 |
Why?
|
| Male | 17 | 2020 | 123000 | 0.150 |
Why?
|
| Retrospective Studies | 10 | 2020 | 37905 | 0.140 |
Why?
|
| Plasmablastic Lymphoma | 1 | 2015 | 37 | 0.130 |
Why?
|
| Thrombocytopenia | 1 | 2000 | 846 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 1 | 2003 | 3981 | 0.130 |
Why?
|
| Prevalence | 3 | 2011 | 3260 | 0.120 |
Why?
|
| Bone Density Conservation Agents | 1 | 2016 | 198 | 0.120 |
Why?
|
| Diphosphonates | 1 | 2016 | 262 | 0.120 |
Why?
|
| Postoperative Complications | 1 | 2008 | 5542 | 0.110 |
Why?
|
| Pain | 1 | 2002 | 1658 | 0.110 |
Why?
|
| Bone Cysts, Aneurysmal | 1 | 2013 | 21 | 0.110 |
Why?
|
| Femoral Neoplasms | 1 | 2013 | 64 | 0.110 |
Why?
|
| Biopsy | 1 | 2020 | 3443 | 0.110 |
Why?
|
| Dasatinib | 1 | 2016 | 862 | 0.110 |
Why?
|
| Tibia | 1 | 2013 | 131 | 0.100 |
Why?
|
| Equipment Failure | 1 | 2012 | 191 | 0.100 |
Why?
|
| Syndrome | 2 | 2009 | 1351 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2016 | 15862 | 0.100 |
Why?
|
| Azygos Vein | 1 | 2011 | 16 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2015 | 6550 | 0.100 |
Why?
|
| Mediastinal Neoplasms | 1 | 2015 | 423 | 0.100 |
Why?
|
| Observer Variation | 1 | 2013 | 671 | 0.100 |
Why?
|
| Adolescent | 5 | 2014 | 31252 | 0.100 |
Why?
|
| Gadolinium DTPA | 1 | 2011 | 172 | 0.100 |
Why?
|
| Patient Positioning | 1 | 2012 | 195 | 0.100 |
Why?
|
| Muscle Neoplasms | 1 | 2011 | 109 | 0.100 |
Why?
|
| Vena Cava, Superior | 1 | 2011 | 78 | 0.100 |
Why?
|
| Thoracic Vertebrae | 1 | 2011 | 186 | 0.090 |
Why?
|
| Young Adult | 5 | 2015 | 21445 | 0.090 |
Why?
|
| Reference Standards | 1 | 2011 | 339 | 0.090 |
Why?
|
| Imidazoles | 1 | 2016 | 999 | 0.090 |
Why?
|
| Chronic Disease | 2 | 2009 | 1819 | 0.090 |
Why?
|
| Lumbar Vertebrae | 1 | 2011 | 245 | 0.090 |
Why?
|
| Sciatic Nerve | 1 | 2010 | 112 | 0.090 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2019 | 925 | 0.090 |
Why?
|
| Carcinoma | 2 | 2011 | 2578 | 0.080 |
Why?
|
| Acne Vulgaris | 1 | 2009 | 47 | 0.080 |
Why?
|
| Periosteum | 1 | 2009 | 39 | 0.080 |
Why?
|
| World Health Organization | 1 | 2010 | 316 | 0.080 |
Why?
|
| Radiotherapy | 1 | 2015 | 1824 | 0.080 |
Why?
|
| Ribs | 1 | 2009 | 91 | 0.080 |
Why?
|
| Nerve Block | 1 | 2010 | 176 | 0.080 |
Why?
|
| Catheterization, Central Venous | 1 | 2011 | 354 | 0.080 |
Why?
|
| Necrosis | 1 | 2009 | 580 | 0.080 |
Why?
|
| Kidney Neoplasms | 1 | 2001 | 3022 | 0.070 |
Why?
|
| Child | 5 | 2014 | 29154 | 0.070 |
Why?
|
| Patient Safety | 1 | 2012 | 649 | 0.070 |
Why?
|
| Subtraction Technique | 1 | 2007 | 141 | 0.070 |
Why?
|
| Feasibility Studies | 1 | 2011 | 2292 | 0.070 |
Why?
|
| Osteomyelitis | 1 | 2008 | 236 | 0.070 |
Why?
|
| Aged, 80 and over | 5 | 2015 | 29902 | 0.070 |
Why?
|
| Lower Extremity | 2 | 2010 | 299 | 0.070 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2015 | 1664 | 0.060 |
Why?
|
| Follow-Up Studies | 4 | 2012 | 14889 | 0.060 |
Why?
|
| Infant | 3 | 2009 | 13310 | 0.060 |
Why?
|
| Prognosis | 5 | 2012 | 21713 | 0.060 |
Why?
|
| Wound Healing | 1 | 2009 | 815 | 0.060 |
Why?
|
| Disease-Free Survival | 3 | 2011 | 10001 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 4938 | 0.050 |
Why?
|
| Survival Rate | 3 | 2012 | 12221 | 0.050 |
Why?
|
| Orthopedic Procedures | 1 | 2003 | 146 | 0.050 |
Why?
|
| Nerve Compression Syndromes | 1 | 2001 | 30 | 0.050 |
Why?
|
| Benchmarking | 1 | 2024 | 273 | 0.050 |
Why?
|
| Spine | 1 | 2023 | 293 | 0.050 |
Why?
|
| Bone Screws | 1 | 2002 | 84 | 0.050 |
Why?
|
| Pseudarthrosis | 1 | 2001 | 5 | 0.050 |
Why?
|
| Risk Factors | 3 | 2011 | 17523 | 0.050 |
Why?
|
| Treatment Outcome | 5 | 2015 | 32848 | 0.050 |
Why?
|
| Combined Modality Therapy | 4 | 2015 | 8865 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2010 | 9180 | 0.050 |
Why?
|
| Genes, Wilms Tumor | 1 | 2001 | 64 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2009 | 16273 | 0.050 |
Why?
|
| Bone Diseases, Developmental | 1 | 2001 | 70 | 0.050 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2002 | 176 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2012 | 12873 | 0.050 |
Why?
|
| Neurofibromatosis 1 | 1 | 2001 | 144 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 4744 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 4320 | 0.040 |
Why?
|
| Texas | 1 | 2009 | 6311 | 0.040 |
Why?
|
| Doxorubicin | 2 | 2015 | 3005 | 0.040 |
Why?
|
| Arteries | 1 | 2019 | 274 | 0.040 |
Why?
|
| Disease Progression | 1 | 2009 | 6682 | 0.040 |
Why?
|
| Neoplasms | 1 | 2024 | 15193 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2024 | 2218 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2000 | 712 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2009 | 4975 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2001 | 1863 | 0.030 |
Why?
|
| src-Family Kinases | 1 | 2016 | 478 | 0.030 |
Why?
|
| Etoposide | 1 | 2015 | 870 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2015 | 864 | 0.030 |
Why?
|
| Prednisone | 1 | 2015 | 984 | 0.030 |
Why?
|
| Time Factors | 1 | 2006 | 12926 | 0.030 |
Why?
|
| Ireland | 1 | 2011 | 30 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2015 | 1914 | 0.020 |
Why?
|
| Vincristine | 1 | 2015 | 1511 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2015 | 1450 | 0.020 |
Why?
|
| Radiology Information Systems | 1 | 2011 | 114 | 0.020 |
Why?
|
| Rituximab | 1 | 2015 | 1528 | 0.020 |
Why?
|
| Sample Size | 1 | 2010 | 202 | 0.020 |
Why?
|
| Femur | 1 | 2010 | 158 | 0.020 |
Why?
|
| Breast | 1 | 2016 | 1344 | 0.020 |
Why?
|
| Body Height | 1 | 2010 | 231 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 11538 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2011 | 351 | 0.020 |
Why?
|
| Sheep | 1 | 2009 | 258 | 0.020 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2009 | 209 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2015 | 3001 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2012 | 1742 | 0.020 |
Why?
|
| ROC Curve | 1 | 2011 | 1183 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2000 | 8223 | 0.020 |
Why?
|
| Linear Models | 1 | 2010 | 1085 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2015 | 2054 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2016 | 2518 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 2803 | 0.020 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2011 | 509 | 0.020 |
Why?
|
| Comorbidity | 1 | 2011 | 2352 | 0.020 |
Why?
|
| Skin | 1 | 2010 | 1259 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 4298 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2009 | 2843 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2009 | 4844 | 0.010 |
Why?
|
| United States | 1 | 2011 | 15433 | 0.010 |
Why?
|
| Animals | 1 | 2009 | 59536 | 0.000 |
Why?
|